Pulmonary fibrosis model

Pulmonary fibrosis is a late-stage manifestation of a variety of lung diseases that involve the proliferation of fibroblasts and the accumulation of a significant amount of extracellular matrix. This process is accompanied by inflammatory injury and destruction of tissue structure. Daxiang employs the IBAC M1 chip to construct a human-derived pulmonary fibrosis model using the patient's primary tissue. This model offers high bionics and high throughput advantages, which can aid in the development of new anti-fibrosis drugs.

  • Research on the pathogenesis of pulmonary fibrosis
  • Anti-pulmonary fibrosis drug research and development
Sample data
Pulmonary Fibrosis: Principles of Microphenotyping on a Chip
Collagen shrinkage combined with AI image recognition on the IBAC S1 chip is a new index for anti-fibrotic drug evaluation, with the advantages of low cost and high sensitivity
Anti-pulmonary fibrosis drug evaluation
The microphenotypes of pirfenidone, entinostat, and talabox mesylate showed antifibrotic efficacy starting at concentrations of 1.5 mM, 0.625 μM, and 160 μM, which were consistent with the effective concentrations reported in the literature. The three drugs have different anti-fibrotic pharmacodynamic mechanisms, but share universal microscopic phenotype indicators that are used for evaluating their effectiveness as anti-fibrotic drugs.
Model Catalog